Sign Out
Each 10 ml vial contains: Nimotuzumab 50.0 mg, Dibasic sodium phosphate (Na2HPO4) 18.0 mg, Monobasic sodium phosphate (NaH2PO4) 4.5 mg, Sodium chloride 86.0 mg, Polysorbate 80 2.0 mg, Water for injection ad 10 ml.
Cimaher (Nimotuzumab) is a recombinant humanized monoclonal antibody that binds to the extracellular domain of human epidermal growth factor receptor (EGFR). The humanized antibody (IgG1) was obtained by transplanting the complementarity determining regions (CDRs) of the murine IgG2a monoclonal antibody (ior egf/r3) to a human framework assisted by computer modeling. A reshaped antibody was constructed using the light and heavy chains (REI and Eu, respectively) as human immunoglobulin framework for CDR-grafting. Cimaher is produced through mammalian cell culture of non-secreting NSO cells and has a molecular weight of 151 KD.
